CLINICAL TRIAL FOR THE COMPARATIVE EVALUATION OF ACID SUPPRESSION AND SYMPTOM MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE WITH THE ADMINISTRATION OF TEGOPRAZAN OR PANTOPRAZOLE

Launched by CARNOT LABORATORIES · May 20, 2025

Keywords

ClinConnect Summary

This clinical trial is comparing two medications, tegoprazan and pantoprazole, to see which one works better at relieving symptoms of gastroesophageal reflux disease (GERD) in adults. GERD can cause uncomfortable symptoms like heartburn and regurgitation, and the trial aims to find out how many patients feel better after taking one of these medications for four weeks.

To be eligible for the trial, participants must be adults aged 65 and older with a recent diagnosis of GERD or non-erosive reflux disease (NERD) confirmed by an endoscopy and specific tests that show acid levels in the esophagus. Those with certain health conditions, allergies to the medications, or recent surgeries on the stomach or esophagus cannot participate. If you join the trial, you’ll receive one of the two medications and be monitored to see how well it helps your symptoms over the study period. This research could help improve treatments for GERD in the future!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • With endoscopic diagnosis of GERD or NERD (endoscopy ≤ 15 days old)
• • With positive impedance pHmetry results (pHmetry ≤ 15 days old)
• • With recurrent symptoms of heartburn and regurgitation for a previous period ≥ 3 months old
• Exclusion Criteria:
• • With known hypersensitivity to tegoprazan, pantoprazole, or any of the components of each formulation
• • Subjects with concomitant administration of atazanavir, nelfinavir or rilpivirine
• • Nephropathic and/or hepatopathic subjects (including non-alcoholic hepatitis)
• • Subjects with upper gastrointestinal tract bleeding
• • Subjects with gastric and/or duodenal ulcer 2 months prior to screening
• • Subjects with a history of esophageal or gastric surgery